Douglas B. Johnson

2 ta ish

Vanderbilt University Medical Center

1. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

   Satya Das, Douglas B. Johnson

   Sharh maqolaOAOchiq kirish20192 iqtibos

   ABIABI:AkademIndex/2026.other.097093

2. Molecular Pathways: Targeting <i>NRAS</i> in Melanoma and Acute Myelogenous Leukemia

   Douglas B. Johnson, Keiran S.M. Smalley, Jeffrey A. Sosman

   Sharh maqola20142 iqtibos

   ABIABI:AkademIndex/2026.other.574571